RefleXion Medical reaps $100M in series C round

RefleXion Medical raised more than $100 million in a series C round of funding. (Pixabay)

RefleXion Medical, which is developing a biologically guided radiotherapy platform for targeted cancer treatment, raised more than $100 million in a series C round of funding.

The round was led by The Rise Fund, which is managed by TPG Growth. Other investors in the round included T. Rowe Price Associates, China-focused healthcare investment firm GT Healthcare Capital Partners and all existing investors including Sofinnova Partners, KCK Group, Venrock and corporate investors Pfizer Venture Investments and Johnson & Johnson Innovation.

Hayward, Calif.-based RefleXion is developing a device that transforms radiation therapy—which has long been used to treat localized cancer—into a new option for patients whose tumors have metastasized.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Current systems have significant limitations our platform addresses,” Todd Powell, RefleXion’s chief executive, said in a statement. “We believe many of the 600,000 U.S. patients with metastatic cancer each year could benefit from our unique ability to accurately irradiate multiple tumors in the same session. Another 750,000 U.S. patients diagnosed annually with early stage disease may benefit from our system automatically compensating for tumor motion while precisely targeting the disease.”

Traditionally, radiation therapy takes two steps: MR or CT imaging, which shows physicians where to deliver radiation, and the radiation itself. RefleXion combines positron emission tomography (PET) imaging and radiation in one device. It uses PET imaging to locate tumors, where a radioactive tracer collects. The tracer continuously emits signals, which serve as targets for radiation beams.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.